Articles tagged with Ovarian Cancer
A recent study published in the Journal of Community Genetics found that only one in twenty-two high-risk women received BRCA genetic counseling. Despite having a diverse population, no significant differences were associated with factors like age, race, or family size. The researchers urge providers and patients to be more aware of th...
A new study found that ovarian cancer cells become more aggressive and proliferate faster when adhering to soft tissues compared to stiffer environments. The research team used novel techniques to measure cell forces, revealing a three-fold increase in traction forces on soft surfaces for metastatic cells.
Researchers found a key indicator of ovarian cancer aggressiveness in the glutamine ratio between external and internal sources. A high ratio is associated with tumor aggression and poor survival rates.
Researchers at Georgia State University identify two enzymes that suppress proteins important for cell survival and chemoresistance in ovarian cancer. Their findings suggest inhibiting these enzymes could be a novel therapeutic approach to overcoming resistance.
A new study elucidates how BRCA gene loss accelerates chromosome rearrangements, impairing homologous recombination repair. This discovery could help clinicians guide patient treatment for BRCA mutations of uncertain significance.
Scientists have identified a potential new strategy to treat ovarian cancer by targeting multiple growth factors. By blocking several avenues that tumour cells use to escape eradication, researchers hope to develop new anticancer drugs that target ovarian tumour growth.
Researchers inhibit heat shock protein 90, shutting off proteases that help ovarian cancer cells escape and spread. In mouse studies, ganetespib treatment reduced metastases, indicating potential therapeutic target for ovarian cancer.
The Bezos family's $20 million donation will support the development of novel cancer immunotherapies for various solid tumor cancers. The gift promises to save lives by expanding the use of immunotherapy to treat a range of deadly cancers.
Researchers at Fox Chase Cancer Center have identified FAK as a potential target for epithelial ovarian cancer treatment. By inhibiting the activity of FAK, they found that STAT3 activation was reduced, suggesting that targeting this enzyme could also inhibit the action of STAT3 in epithelial ovarian cancer cells.
Researchers from Fox Chase Cancer Center found that NEDD9 protein activates oncogenic signaling pathways in cancer cells, encouraging metastases. The study suggests the protein plays an important role in initial development and dissemination of ovarian cancer.
Researchers uncover complement pathway as primary immune mechanism driving endometriosis and ovarian cancer development. The discovery may lead to targeted preventive measures, such as immune therapy, for women with endometriosis at increased cancer risk.
Researchers discovered two new genes, NEIL2 and OGG1, that modulate the risk of breast and ovarian cancer in women with high-risk mutations. The genes affect an alternative DNA repair pathway and may have implications for treatments like PARP inhibitors.
A new study found that ovarian cancer patients' disease-free survival rates significantly improved over time, particularly among those with poorer initial prognoses. The research suggests that considering the time elapsed since remission may provide a more accurate prognosis and inform better follow-up care decisions.
Researchers at the University of Texas MD Anderson Cancer Center found that blocking prolactin signaling can induce autophagy in cancer cells, leading to their death. In preclinical research, treatment with a prolactin-mimicking peptide reduced tumor weight by 50% and led to increased expression of autophagy genes.
A groundbreaking study led by TGen has identified a genetic mutation in the SMARCA4 gene as the primary driver of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), a rare and aggressive form of ovarian cancer. This discovery holds promise for developing targeted therapies and improving diagnosis.
Scientists have identified a set of proteins called TAFs that may play a role in the development of ovarian cancer. Studies found that these proteins are overexpressed or underexpressed in 73% of tumors, suggesting they could be potential targets for new treatments.
A new glycoprofiling test has been developed to halve the number of false-positives in ovarian cancer diagnoses, sparing women from unnecessary worry and further testing. The test targets a specific sugar molecule on the CA125 protein, which is only present in women with ovarian cancer.
Researchers at Tel Aviv University propose a new nanoscale drug-delivery system to tackle aggressive ovarian cancer using a cluster of nanoparticles called gagomers. The system accumulates in tumors, producing dramatic therapeutic benefits and reducing toxic accumulation in healthy organs.
A large international study found that women with BRCA1 mutations who underwent preventive ovarian surgery before age 35 had a 77% reduction in total mortality risk. In contrast, women with BRCA2 mutations may delay this procedure until their 40s.
Researchers have developed a biologic drug that prevents the production of HE4 protein, allowing ovarian cancer cells to grow aggressively and resist chemotherapy. The novel biologic has shown promising results in cell and animal models, increasing the potential for improved treatment and survival rates for women with ovarian cancer.
A University of Colorado study used a COXEN model to match tumors with optimal drugs, significantly extending patient survival. The model analyzed genetic data from thousands of tumor samples to identify response patterns.
Two proteins, phospholipase Cγ1 and growth factor receptor bound protein 2 (Grb2), compete for binding to FGFR2 with distinct effects on cancer cell behavior. High levels of Plcγ1 lead to increased metastasis, while high Grb2 levels inhibit this process.
The University of South Florida and FORCE have received a PCORI award to expand a health data network for hereditary breast and ovarian cancer research. The ABOUT Network will collect comprehensive clinical data, engage patients, and advance patient-centered studies.
A new study estimates that one in five women with ovarian cancer has an inherited genetic mutation that increases their risk of developing the disease. The research identified 222 inherited genetic variants associated with ovarian cancer, including major changes in genes critical for DNA repair and cell division.
Researchers at Case Comprehensive Cancer Center have identified a microRNA biomarker, miR-181a, that predicts treatment response in ovarian cancer. Elevated levels of miR-181a are associated with chemotherapy resistance and disease progression.
A study by Manchester scientists found that women who undergo risk-reducing surgery have increased survival rates compared to those who don't. The research suggests that removing ovaries and fallopian tubes can reduce the risk of both ovarian and breast cancer by half.
Researchers at Cedars-Sinai have discovered a 10-gene biomarker panel that can identify the aggressiveness of ovarian cancer, predict survival outcomes, and inform novel therapeutic strategies. The study suggests that this biomarker panel may have predictive value and biological relevance for treating patients with ovarian cancer.
Researchers at Rutgers University have developed a targeted drug delivery system that successfully treats advanced-stage ovarian cancer in mice. The treatment involves using small inhibiting RNA molecules to decrease excess CD44 protein in cancer cells while treating with anti-cancer drug paclitaxel.
A microchip-based device developed by MGH researchers may simplify the monitoring of patients' response to treatment for ovarian cancer. The team isolated and identified tumor cells from ascites, an accumulation of fluid in the abdomen that often occurs in abdominal cancers.
Scientists at Fred Hutchinson Cancer Center developed a method to count tumor-infiltrating T lymphocytes reliably and quickly, which correlates with improved survival rates. The technology has the potential to predict treatment response, cancer recurrence, and disease-free survival earlier and more effectively.
A comprehensive study reveals unprecedented genetic variation in ovarian cancer, highlighting potential new pathways for therapeutic intervention. The research suggests that sampling and sequencing of multiple disease sites may be required for effective targeted treatments.
The EORTC study found that baseline recorded health-related quality of life parameters provided additional prognostic information for survival in eleven types of cancer, including brain, breast, and colorectal cancers. The specific health-related quality of life parameters found to be predictive for survival varied by cancer site.
A study by UCL researchers found that abnormal levels of female hormones are a possible explanation for why women with BRCA1/2 mutations develop breast and ovarian cancer. The research suggests that targeting these hormones could lead to new ways of preventing cancers in high-risk women.
A new study identifies cancer-specific gene signatures for breast, lung, prostate, and ovarian cancers using surprisal analysis, a thermodynamics-based approach. This method allows researchers to understand how cellular energy is expended in cancer cells and identify potential biomarkers for early detection and therapy.
A new study found that targeted treatment and conventional chemotherapy can be effective in treating ovarian cancer, particularly in women with BRCA gene mutations. The treatment combination showed promising results in patients who had previously developed resistance to PARP inhibitor drugs.
A clinical trial found that cediranib, a biological therapy, extended the time before ovarian cancer recurred and increased overall survival by up to 30% compared to chemotherapy alone. The treatment showed incremental improvements in progression-free and overall survival.
Researchers have identified fibroblast growth factor 18 (FGF18) as a predictive marker for poor overall survival in ovarian cancer patients. The study found that overexpression of the FGF18 gene is associated with enhanced tumor blood vessel formation and expression of cancer-promoting cytokines.
Researchers at Massachusetts General Hospital identify fibroblast growth factor 18 (FGF18) as a predictive marker for poor overall survival in ovarian cancer patients. Overexpression of the gene encoding FGF18 was associated with enhanced tumor blood vessel formation and expression of cancer-promoting cytokines.
A new study found that certain immune cells help cancer stem cells survive and thrive. This finding has significant implications for the development of targeted therapies to eliminate cancer.
A 12-year study found CA-125 to have a 99.9% specificity in detecting high-grade invasive ovarian cancers at curable stages, while the test failed to detect two borderline cases. The study's results suggest CA-125 as a promising first step in early disease detection.
A Mayo Clinic study found that patients undergoing enhanced recovery pathway (ERP) for gynecologic surgery experienced decreased narcotic use, earlier discharge, and cost savings. The ERP standardized postoperative management to reduce complications and improve patient satisfaction.
A new screening strategy for ovarian cancer has shown high specificity in detecting the disease before it becomes lethal. The two-stage approach incorporates changes in a blood protein called CA125 and has been found to have a positive predictive value of 40% for invasive ovarian cancer.
A new biomarker, PROVAR, predicts time to ovarian cancer recurrence and distinguishes between high-risk patients. Analysis of protein biomarkers may help determine treatment plans for ovarian cancer patients.
Researchers identified protein biomarkers that predict ovarian cancer recurrence and chronic obstructive pulmonary disease (COPD) development. The findings suggest a potential for using protein analysis to predict patient outcomes and guide treatment decisions in both diseases.
A comprehensive compendium of mutational processes explains most mutations found in 30 common cancer types, revealing the biological processes responsible. The study identifies a family of enzymes linked to over half of cancer types, and finds that DNA damage from viruses may cause collateral genetic changes.
A new study reveals that young female cancer survivors experience significant impairment in quality of life due to fertility concerns. The study found that women's perception of their own fertility status was the most influential factor in determining overall quality of life.
Researchers have direct evidence that epithelial-to-mesenchymal transition (EMT) occurs in human ovarian cancer patients, resulting in unique characteristics and resistance to chemotherapy. This finding highlights the need for combination therapy targeting both primary tumors and metastatic cells.
Researchers developed statistical models that predict individual women's risk of each cancer based on commonly known risk factors. The models were able to accurately calculate risk ranges from 0.5% to 29.5% over the next 20 years, providing a valuable tool for clinical decision-making.
A large study of 23,000 people in Italy and Switzerland found a strong link between family history of cancer and increased risk of developing different types of cancer. The study revealed associations between specific cancers, such as oral and pharyngeal cancer, ovarian cancer, and prostate cancer, with a range of risk increases
Researchers found that ovarian cancer cells colonize milky spots in the omentum, which promotes cell growth and spread. The study suggests an alternative model of omental colonization, where both milky spots and fat cells play a role in attracting cancer cells.
Scientists have solved a key piece of the puzzle on how BRCA1 gene mutations predispose women to breast and ovarian cancers. The answer lies in the way estrogen rushes in to rescue damaged cells whose healthy functioning has been altered by oxidative stress.
A new study reveals low uptake of genetic testing for cancer-causing mutations in affected families in France. Despite steady increase in tests for BRCA1/2, MMR mutation testing remains under-used, putting whole families at risk.
African-American women with breast cancer are more likely to carry inherited genetic mutations that increase their risk for breast cancer. Genetic testing can help identify at-risk family members and provide personalized strategies for early detection and prevention.
Researchers developed a novel approach to make ovarian cancer cells susceptible to an antitumor drug, potentially improving treatment outcomes. The strategy targets telomeres and shows promise in treating other epithelial cancers.
A clinical trial led by Penn Medicine found that olaparib was effective against advanced pancreatic and prostate cancers in patients carrying BRCA 1/2 mutations. The therapy showed promise in halting disease progression, even in patients whose tumors did not shrink.
A major international study has found that sequence differences in a gene crucial to chromosome integrity predispose individuals to certain cancers. The study, published in Nature Genetics, identified variations in the TERT gene as influencing telomere length and breast and ovarian cancer risk.
The team identified 21 microRNAs associated with ovarian cancer survival and 838 target genes linked to its progression. The findings suggest a network-based approach can predict cancer survival and recurrence more accurately than individual biomarkers.
A Northwestern University study has developed a pioneering biophotonics technology to detect ovarian cancer by analyzing cells from the cervix or uterus. The partial wave spectroscopic microscopy technique shows diagnostic changes in these cells even when they appear normal under a microscope, offering a potential breakthrough in early...
Researchers have identified the molecular mechanisms behind two rare diseases: giant axonal neuropathy and ovarian cancer. In GAN, mutations in gigaxonin disrupt neural protein degradation, leading to neurofilament accumulation. Meanwhile, ATP11B facilitates cisplatin resistance in ovarian cancer cells by mediating platinum export.
A study found that ATP11B expression is correlated with higher tumor grade and cisplatin-resistance in human ovarian cancer samples. Loss of ATP11B restored sensitivity to cisplatin and reduced ovarian tumor growth in mice.